692 research outputs found

    Resolution, Relief, And Resignation:A Qualitative Study Of Responses To Misfit At Work

    Get PDF
    Research has portrayed person–environment (PE) fit as a pleasant condition resulting from people being attracted to and selected into compatible work environments; yet, our study reveals that creating and maintaining a sense of fit frequently involves an effortful, dynamic set of strategies. We used a two-phase, qualitative design to allow employees to report how they become aware of and experience misfit, and what they do in response. To address these questions, we conducted interviews with 81 individuals sampled from diverse industries and occupations. Through their descriptions, we identified three broad responses to the experience of misfit: resolution, relief, and resignation. Within these approaches, we identified distinct strategies for responding to misfit. We present a model of how participants used these strategies, often in combination, and develop propositions regarding their effectiveness at reducing strain associated with misfit. These results expand PE fit theory by providing new insight into how individuals experience and react to misfit—portraying them as active, motivated creators of their own fit experience at work

    The person-based nature of prejudice: Individual difference predictors of intergroup negativity

    Get PDF
    Person-based factors influence a range of meaningful life outcomes, including intergroup processes, and have long been implicated in explaining prejudice. In addition to demonstrating significant heritability, person-based factors are evident in expressions of generalised prejudice, a robust finding that some people (relative to others) consistently score higher in prejudice towards multiple outgroups. Our contemporary review includes personality factors, ideological orientations (e.g., authoritarianism), religiosity, anxiety, threat, disgust sensitivity, and cognitive abilities and styles. Meta-analytic syntheses demonstrate that such constructs consistently predict prejudice, often at the upper bounds of effect sizes observed in psychological research. We conclude that prejudice theories need to better integrate person- and situation-based factors, including their interaction, to capture the complexity of prejudice and inform intervention development

    The Association of Cognitive Ability with Right-wing Ideological Attitudes and Prejudice: A Meta-analytic Review

    Get PDF
    The cognitive functioning of individuals with stronger endorsement of right-wing and prejudiced attitudes has elicited much scholarly interest. Whereas many studies investigated cognitive styles, less attention has been directed towards cognitive ability. Studies investigating the latter topic generally reveal lower cognitive ability to be associated with stronger endorsement of right-wing ideological attitudes and greater prejudice. However, this relationship has remained widely unrecognized in literature. The present meta-analyses revealed an average effect size of r =-.20 [95% confidence interval (95% CI) [-0.23, -0.17]; based on 67 studies, N=84 017] for the relationship between cognitive ability and right-wing ideological attitudes and an average effect size of r=-.19 (95% CI [-0.23, -0.16]; based on 23 studies, N=27 011) for the relationship between cognitive ability and prejudice. Effect sizes did not vary significantly across different cognitive abilities and sample characteristics. The effect strongly depended on the measure used for ideological attitudes and prejudice, with the strongest effect sizes for authoritarianism and ethnocentrism. We conclude that cognitive ability is an important factor in the genesis of ideological attitudes and prejudice and thus should become more central in theorizing and model building

    A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

    Get PDF
    Meeting abstrac

    Measurements of the pp → ZZ production cross section and the Z → 4ℓ branching fraction, and constraints on anomalous triple gauge couplings at √s = 13 TeV

    Get PDF
    Four-lepton production in proton-proton collisions, pp -> (Z/gamma*)(Z/gamma*) -> 4l, where l = e or mu, is studied at a center-of-mass energy of 13 TeV with the CMS detector at the LHC. The data sample corresponds to an integrated luminosity of 35.9 fb(-1). The ZZ production cross section, sigma(pp -> ZZ) = 17.2 +/- 0.5 (stat) +/- 0.7 (syst) +/- 0.4 (theo) +/- 0.4 (lumi) pb, measured using events with two opposite-sign, same-flavor lepton pairs produced in the mass region 60 4l) = 4.83(-0.22)(+0.23) (stat)(-0.29)(+0.32) (syst) +/- 0.08 (theo) +/- 0.12(lumi) x 10(-6) for events with a four-lepton invariant mass in the range 80 4GeV for all opposite-sign, same-flavor lepton pairs. The results agree with standard model predictions. The invariant mass distribution of the four-lepton system is used to set limits on anomalous ZZZ and ZZ. couplings at 95% confidence level: -0.0012 < f(4)(Z) < 0.0010, -0.0010 < f(5)(Z) < 0.0013, -0.0012 < f(4)(gamma) < 0.0013, -0.0012 < f(5)(gamma) < 0.0013

    Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

    Get PDF
    Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without D
    corecore